Advancing a New Class of Immunotherapies

At another stop on the Road to 50 States, Eddie Sullivan, CEO, President and Co-Founder at SAb Biotherapeutics, talks to Nigel about how the company is producing targeted, highly potent, fully human polyclonal antibodies without the need for human donors.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

SAb Biotherapeutics

SAB Biotherapeutics is a clinical-stage biopharmaceutical company with a unique approach to immunotherapies –unleashing the power of the body’s natural defense system to address the complexity, emergence and mutation of human disease.

The body’s natural defense system produces polyclonal antibodies against invaders such as viruses, allergens, bacteria, toxins, and other pathogens. We’ve harnessed the natural power of the human immune response in a therapeutic engine, the DiversitAb™ platform, to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors.

Made possible by the sophistication of science and genius of nature, SAB’s innovative DiversitAb™ platform enables a scalable and reliable production of highly-potent polyclonal antibody therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers.